Rare & Hereditary Cancers

Although less prevalent, rare and inherited malignancies present major diagnostic and therapy difficulties because of their distinct genetic patterns and low awareness. Less than 20% of all cancer cases are rare cancers—such as neuroendocrine tumours, certain paediatric malignancies, and sarcomas. Many times lacking conventional treatment guidelines, these cancers cause delays in diagnosis and specialised care.
Conversely, hereditary malignancies are connected to inherited genetic defects handed down through generations. Mutations in genes, including BRCA1, BRCA2, TP53, and MLH1 raise cancer risk, including those of breast, ovarian, colorectal, and prostate cancer. Genetic counselling and early screening initiatives help those with a family history of cancer find malignancies at a treatable stage.
For those with these tumours, developments in genetic testing, tailored treatments, and individualised medicine have brightened their prospects. Effective management of both rare and hereditary tumours depends critically on awareness, early intervention, and multidisciplinary care.